Disease System Analysis: Basic Disease Progression Models in Degenerative Disease

PurposeTo describe the disease status of degenerative diseases (i.e., type 2 diabetes mellitus, Parkinson’s disease) as function of disease process and treatment effects, a family of disease progression models is introduced.MethodsDisease progression is described using a progression rate (Rdp) acting on the synthesis or elimination parameters of the indirect response model. Symptomatic effects act as disease-dependent or -independent effects on the synthesis or elimination parameters. Protective drug effects act as disease dependent or -independent effects on Rdp.ResultsSimulations with the ten disease models show distinctly different signature profiles of treatment effects on disease status. Symptomatic effects result in improvement of disease status with a subsequent deterioration. Treatment cessation results in a disease status equal to the situation where treatment had not been applied. Protective effects result in a lasting reduction, or even reversal, of the disease progression rate and the resulting disease status during the treatment period. After cessation of treatment the natural disease course will continue from the disease status at that point.ConclusionDisease system analysis constitutes a scientific basis for the distinction between symptomatic versus protective drug effects in relation to specific disease processes as well as the identification of the exposure-response relationship during the time-course of disease.

[1]  M Danhof,et al.  Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[2]  L. Peletier,et al.  Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan. , 2002, European journal of pharmacology.

[3]  C C Peck,et al.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[5]  Jean-Pierre Devogelaer,et al.  Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.

[6]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[7]  C. Olanow,et al.  The scientific basis for the current treatment of Parkinson's disease. , 2004, Annual review of medicine.

[8]  K E Peace,et al.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Sheiner Is intent-to-treat analysis always (ever) enough? , 2002, British journal of clinical pharmacology.

[10]  Malcolm Rowland,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.

[11]  L. Peletier,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.

[12]  P. Jenner,et al.  Pharmacology of dopamine agonists in the treatment of Parkinson’s disease , 2002, Neurology.

[13]  Bruce R. Brodie,et al.  Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial , 2004 .

[14]  M. Guttman,et al.  Dopamine agonist monotherapy in Parkinson's disease , 2002, The Lancet.

[15]  R. Lavielle,et al.  The mode of action and clinical pharmacology of gliclazide: a review. , 1991, Diabetes research and clinical practice.

[16]  D. Rubin,et al.  Intention‐to‐treat analysis and the goals of clinical trials , 1995, Clinical pharmacology and therapeutics.

[17]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[18]  J. Brotchie,et al.  Drugs in development for Parkinson's disease. , 2004, Current opinion in investigational drugs.

[19]  E Niclas Jonsson,et al.  More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.

[20]  L. V. D. van de Putte,et al.  Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. , 1997, British journal of rheumatology.

[21]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.

[22]  P. Lipsky,et al.  Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[23]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[24]  N. Holford,et al.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. , 2003, British journal of clinical pharmacology.

[25]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[26]  Timothy Goggin,et al.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.

[27]  K. Johnson An Update. , 1984, Journal of food protection.

[28]  L. Peletier,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. , 2002, The Journal of pharmacology and experimental therapeutics.

[29]  W. Colburn,et al.  Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing , 2003, Journal of clinical pharmacology.

[30]  K E Peace,et al.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[32]  P. Jenner Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease , 2003, Current opinion in neurology.

[33]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[34]  E. Bock,et al.  Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate , 1999, Annals of the rheumatic diseases.

[35]  Carlos R Plata-Salamán,et al.  Biomarker discovery and validation: technologies and integrative approaches. , 2004, Trends in biotechnology.

[36]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[37]  W. Colburn,et al.  Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic Modelling , 2003, Clinical pharmacokinetics.

[38]  F E Shaffer,et al.  Elusive Goal , 1979, Science.

[39]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[40]  Mechanism-Based Modeling of the Pharmacodynamic Interaction of Alphaxalone and Midazolam in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[41]  B. Månsson,et al.  Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.

[42]  K. Peace,et al.  The effect of tacrine and lecithin in Alzheimer's disease , 2004, European Journal of Clinical Pharmacology.

[43]  Meindert Danhof,et al.  A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. , 2002, The Journal of pharmacology and experimental therapeutics.

[44]  L. Lesko,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.

[45]  W. Jusko,et al.  Characterization of four basic models of indirect pharmacodynamic responses , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[46]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[47]  P H van der Graaf,et al.  A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[48]  A. Stoessl,et al.  New concepts and tools in imaging for the study of neurodegenerative disease. , 2003, Journal of neural transmission. Supplementum.

[49]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[50]  P. Richette,et al.  Structure-modifying agents for osteoarthritis: an update. , 2004, Joint, bone, spine : revue du rhumatisme.

[51]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[52]  B. Ravina,et al.  Neuroprotection in Parkinson's Disease: An Elusive Goal , 2007, Seminars in neurology.